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Summary
Pain problems associated with lesion, disorder or dysfunction of the central nervous 
system are a common and prominent problem.  The objective of this review is to sum-
marize recent advances in our understanding of the etiology, clinical presentation, and 
treatment of central pain (CP), with emphasis being placed on studies published within 
the recent years. The incidence, qualities of the pain experience, associated sensory 
abnormalities, and other characteristics are discussed. Particular attention is paid to CP 
associated with stroke as the most prominent and best studied of the many CP problems. 
In general, there is poor understanding of the pathophysiology of CP, problems are often 
severe and intractable, and treatment is typically difficult. The goal of treatment sho-
uld be pain reduction rather than complete pain relief. Recent studies have indicated 
possible roles for tricyclic antidepressants, antiseizure medications, and motor cortex 
stimulation in the treatment of CP. Surgical procedures have been used for specific cau-
ses of CP, but no one surgical technique helps relieve pain over the long term in all CP 
patients. Perhaps because of the lack of clinical trials, treatment is still largely based on 
traditional prescribing methods and anecdotal evidence. Our poor understanding of the 
etiology of central pain and the relative lack of effective treatments emphasize the need 
for further research into this disorder.
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1. IntroductIon
First described in 1883, central nervous system (CNS) lesions are frequently 
overlooked as a cause of pain, predominantly because of a lack of knowledge 
about its characteristics [1]. However, so-called central pain (CP) states are far 
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from uncommon. They affect approximately 8% of stroke patients, 10% of indi-
viduals with Parkinson’s disease, 25% of multiple sclerosis sufferers, over 50% 
of individuals with spinal cord injuries (SCIs), and up to 80% of patients with 
syringomyelia [2-6]. In addition, CP has been described under more unusual 
circumstances such as with vascular malformations, epilepsy, and after neu-
rosurgery and subarachnoid hemorrhage. Less is known about the prevalence 
and characteristics of CP  in other CNS diseases, and the lack of clear diagnostic 
criteria for CP makes the diagnosis difficult. However, in spite of its prevalence, 
CP remains one of the most challenging syndromes for physicians to treat. Al-
though there are still many aspects of CP that remain poorly understood, recent 
developments in the past few years have shed new light on its pathogenesis and 
treatment.
2. central paIn condItIons
Central pain is defined as „pain initiated or caused by a primary lesion or dysfun-
ction of the CNS“ by the International Association for the Study of Pain (IASP) [7]. 
Recently, a more concise definition has been introduced suggesting that central 
pain is „pain arising as a direct
consequence of a lesion or disease affecting the central somatosensory system“.8  Fo-
llowing this new proposal, the prerequisites for the diagnosis of definite central 
neuropathic pain are: 
• the pain in a neuroanatomically plausible pain distribution;
• a history of a relevant lesion or disease affecting the central somatosensory 
system;
• negative or positive sensory signs confined to the somatotopic representa-
tion of the body within the CNS;
• a diagnostic test confirming a lesion or disease explaining the presence of 
neuropathic pain [8].
The prevalence of shoulder pain in stroke patients has ranged between 11% 
and 14% and for central post-stroke pain (CPSP) between 8% and 35% [9].  The 
difference in the prevalence of CPSP is due to variations in inclusion criteria, the 
definition of CPSP and timing of the study. 
In Parkinson’s disease, chronic pain may arise because of musculoskeletal 
disorders, radiculo-neuritic syndromes, or dystonia [10]. In addition to these 
types of pain, pain may be present with no obvious underlying mechanism and 
is thought to be a direct consequence of the disease, namely a central pain. This 
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type of CP is characterized by painful sensations described as stabbing, aching, 
and burning, predominantly in the more affected side and ‘off’ condition [10,11]. 
In patients with brain trauma, lesions of the somatosensory pathways are often 
obvious and the diagnosis of CP may thus be more straightforward. A systema-
tic study of patients with brain trauma showed that chronic pain in traumatic 
brain injury resembles that of other CP patients [12].
3. MechanIsMs of central paIn
In a classic report published in 1906, Dejerine and Roussy described six pati-
ents with intolerable and persistent pain, accompanied by sensory and motor de-
ficits as a result of lesions of the thalamus [13]. Since then, CP has been described 
after other insults to the CNS – namely, as CPSP. After detailed studies of selecti-
ve neurosurgical interventions, Cassinari and Pagni suggested that interruption 
of the spinothalamocortical pathways is the single common abnormality found 
in individuals with CP [14]. The involvement of these pathways may explain 
how lesions in the spinal cord and brain outside of the thalamus can also ge-
nerate CP. In fact, disorders of the spinal cord such as traumatic injuries and 
syringomyelia are probably associated with the highest incidence of CP [3,4,15]. 
This may be caused by the large relative size of the pain pathways in the spinal 
cord compared with those in the brain. Over the years, many theories have been 
put forward to explain the phenomenon of central pain. First expounded on by 
Head and Holmes in 1911, the idea that the release of the normal inhibitory fun-
ction by lesions in the CNS may be responsible for central pain gained renewed 
prominence in the work of Craig and colleagues [16-18]. According to Craig and 
Bushnell, the sensations of pain and temperature are integrated, with innocuous 
cold normally inhibiting central pain processing [18]. Disruption of this ther-
mosensory integration results in the loss of coldinhibition of burning pain. An 
earlier theory holds that it is the reticular thalamic nucleus that is responsible for 
suppressing the sensations of central pain and hypersensitivity [19,20].
Since Riddoch described the clinical features of patients with CP in 1938, 
dysfunction of the sympathetic nervous system has been implicated in the disor-
der [21]. In 1968, Garcin described autonomic disturbances in some patients with 
CP as manifested by „modificiations in temperature“ [22]. In a study performed 
by Bowsher, a majority of patients with CP exhibited impaired thermal percep-
tion and changes in skin temperature on the affected side, indicating possible 
autonomic dysfunction [23]. In that paper, other signs of autonomic instability in 
patients included `falling asleep easily’ and pain aggravated by orgasm. Other 
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authors reported that a majority of CP patients suffered from cold allodynia and 
exacerbation by cold weather [24,25]. Lending further credence to the implicati-
on of sympathetic mechanisms are reports of pain caused by CNS lesions being 
alleviated by sympathetic nerve blocks [26].
Through experimental models of central pain, we have gained more 
knowledge of CP mechanisms. Gain in neuronal excitability, loss of inhibition, 
and increased facilitation are thought to contribute to a central sensitization and 
disinhibition of pain pathways [27,28]. Recently, there has been an increased fo-
cus on the interaction between inflammation and neuropathic pain. Activated 
microglia was found to maintain neuronal hyperexcitability in the spinal cord 
through an extracellular signal-regulated kinase (ERK)-regulated prostaglan-
din E2 signaling mechanism [29]. Furthermore, a spinal cord injury was found 
to trigger remote changes with upregulation of the microglia activator cystei-
ne–cysteine chemokine ligand 21 (CCL21) and induction of microglia activation 
in the thalamus, changes that were associated with pain behavior [30]. Another 
study also found the chemokine CCL 2 (monocyte-chemoattractant protein-1) 
to be a possible candidate of integrating inflammation and central neuropathic 
pain after SCI [31]. In addition to animal studies pointing towards a role of bra-
in mechanisms in pain following spinal lesions, human brain imaging studies 
emphasize supraspinal pain mechanisms.
4. patophysIology of central paIn
Many years after an already mentioned Head and Holmes proposed theirs 
disinhibition theory – according to which injury to the lateral thalamus sets the 
medial thalamus free from its control – it was found that the lesions anywhere 
in the spinothalamocortical pathway lead to prominent over-activity of the la-
teral thalamus [16]. In either situation, CP is associated with impaired sensation 
evoked by cotton whisp, vibration, roughness, heat and cold. The essential com-
ponent of this hypothesis is that discriminative sensory deficit in CP results in 
disinhibition, which gives rise to spontaneous pain or allodynia. Hyperalgesia 
or allodynia are probably an integral component of CP. In earlier studies, partial 
sensory loss of spinothalamic modalities was considered necessary for the de-
velopment of CP [13,32]. This, however, is not sufficient, as spinothalamic deficit, 
manifested by loss of thermal sensation but without pain, is found in more than 
half of patients [2]. It is therefore not possible to predict the development of CP 
by documenting sensory loss. The most likely mechanism for hyperalgesia and 
partial sensory loss in a body part with normal somatosensory function in a 
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nonpainful body territory is central sensitization of the third order neurons that 
have been partially deafferented [33]. In the clinical setting, central sensitizati-
on can be assessed by mapping the hypersensitive areas, psychophysiological 
measurement of different thresholds, and response to various stimuli [33]. The 
specific neuronal populations which are sensitized in CP are not well known, 
but certain thalamic nuclei are likely to be responsible.
Reticular nucleus surrounding the dorsal and lateral aspect of thalamus pro-
duces GABA-ergic inhibition of relay cells. Groups of deafferented cells in the re-
ticular formation are capable of generating intrinsic bursting activity, which re-
sults in a vicious cycle. The corticothalamic axons traverse through the reticular 
nucleus and innervate these cells by collaterals; hence, cortical lesions may also 
influence the firing pattern of reticular neurons. In neuropathic pain, spontane-
ous neuronal activity is found in the mediodorsal, centrolateral, centromedian, 
and parafascicular nuclei as well as principal sensory nuclei (ventralis caudalis). 
The shift of thalamic neuronal activity from rhythmic burst firing to single-spi-
ke activity is determined by serotonergic, noradrenergic, and cholinergic input 
of thalamic neurons. Noradrenaline originating from the locus ceruleus and se-
rotonergic pathway from dorsal raphe nuclei mediate thalamic burst firing by 
acting through reticular and relay nuclei [34]. The beneficial effect of amitriptyli-
ne and duloxetine may be mediated through the above-mentioned mechanisms. 
Excitatory aminoacids, such as N-methyl-d-aspartate, may mediate nociceptive 
or nonnociceptive inputs to the thalamic nuclei [35]. C-diprenorphine PET stu-
dies in CP have been used to evaluate the distribution of opioid receptors; these 
studies have demonstrated a significant decrease in opioid receptor binding, not 
only in thalamus contralateral to pain, but also in insula, anterior cingulate and 
secondary sensory cortex. The decrease in opioid receptor binding may be due 
to an increase in endogenous release, internalization or dysregulation of recep-
tors and loss of neurons carrying these receptors [36].
5. clInIcal fIndIngs
It is not uncommon for patients to borrow terms from the taxonomy of no-
ciception, or they may invent bizarre, vague terms to describe what they are 
feeling. Consequently, patients may describe dysesthetic types of sensations, 
i.e., painful sensations that may be poorly localized and may vary dramatically 
from one day to the next.
CP patients often experience superficial and deep pain, sometimes separa-
tely, but in most cases concurrently. Pain is constant in 85% of patients, is inter-
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mittent but daily in 15%, and occurs on alternating sides in 7%. The burning 
component is the aspect of pain patients complain about most frequently, but 
aching, pricking, and lancinating are also qualities common to CP with a su-
praspinal source.
Clinical findings include qualitative, spatial, and temporal findings. Quali-
tatively, these patients can have allodynia, dysesthesia and paresthesias. Spatial 
manifestations include abnormal radiation of pain, poor localization, and impa-
ired discrimination. Temporally patients can experience a complex spectrum of 
sensation and can exhibit abnormal latencies from the point of stimulation, with 
after-sensation and sumation. Adaptation and habituation can also occur [37]. 
Clinical examination and testing of CP patients should include interviewing 
the patient regarding symptoms of dysesthesias, hyperesthesias, and paresthesi-
as as with burn ins pain experienced constantly or induced by light touch. Warm 
and cold allodynia symptoms volunteered by the patient should be verified with 
specific testing. If available, quantitative thermal sensory testing should be used 
to determine sidc-to-side asymmetries in thresholds to coding, warmth and heat 
pain; this is the most sensitive technique. Testing for cold may be done at the 
bedside using a flat metal handle wiped with alcohol, air dried, and applied to 
the skin. Also, ethyl chloride spray or an ice cube may be used and provides a 
more intense stimulus. Since most, if not all, CP patients haye some disturban-
ce of sensation, especially temperature alterations-testing and interviewing the 
patient regarding this is crucial to the diagnosis of CP [38].
Central pain after a stroke (CPSP) has varied and often bizarre characteristi-
cs. Disruption of normal sensory pathways may lead to abnormal processing of 
normal sensory stimuli. This dysfunctional activity within the CNS has certa-
in diagnostic patterns, such as burning pain worsened by touch. Characteristic 
symptoms of central pain can be identified by the acronym “Md has cp“:
•	 Muscle pains, described as cramping, band-like constriction, as well as 
crushing, may be quite distressing and disabling for post-stroke patients.
•	 Dysesthesias are the most common abnormal sensations experienced by in-
dividuals with CPSP. The characteristic abnormal, unpleasant, and poorly 
localized sensations are extremely distressing to the patient because they 
convey no useful sensory discriminative information. Centrally evoked dys-
esthesias are characterized by delayed onset after stimulus (temporal or slow 
summation), most often resulting in a burning sensation. 
•	 Hyperpathia, due to CNS disinhibition, involves a heightened response to 
noxious stimuli (evoked pain). Injury within the spinothalamic tract is be-
lieved to give rise to these pathologic sensory phenomena.
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•	 Allodynia is a classic hallmark that is present in more than 50% of patients 
with post-stroke pain. It involves interpretation of nonpainful stimuli (e.g., 
thermal, touch) as being painful or the sensation of pain in a location other 
than the area stimulated. 
•	 Shooting/lancinating pain is intermittent pain with clear sensory discrimi-
native characteristics. A patient with this presentation has little difficulty in 
identifying the location of the pain, unlike the patient with dysesthesias.
•	 Circulatory pain is described as pins and needles, stings, jabs, or walking on 
broken glass. This pain may be mistaken for peripheral neuropathy or for a 
result of poor circulation.
•	 Peristaltic/visceral pain may be expressed as bloating, or fullness of the blad-
der, as well as burning pain with urinary urgency [39].
6. treatMent
6.1. pharmacological treatment
CP is a difficult condition to treat, and pain reduction rather than pain relief 
has to be the goal of the treatment. Conventional analgesics and opioids have been 
noted to be ineffective [40,41]. According to the results of an uncontrolled study, 
only 20% of patients with CP reported a brief reduction of pain after IV morphine, 
and there are no trials indicating a good efficacy of oral opioids in CPSP [42].
Numerous other drugs have been used in the treatment of CP. Despite the 
high frequency of this disorder, its severity, and its great impact on quality of 
life, there is amazingly little scientific evidence on how to treat CP. Randomized 
controlled studies are rare and include only small numbers of patients. Some of 
the studies include patients with peripheral neuropathic pain – which is susta-
ined by specific peripheral mechanisms and thus might respond differently to 
pharmacologic intervention [43,44]. 
Amitriptyline was the first oral drug proven to be effective in CPSP in a small 
placebo-controlled, crossover study [25].  Recently, lamotrigine was shown to be 
a well tolerated and moderately effective compound for the treatment of CPSP 
in the largest placebo-controlled study conducted to date [45]. As a consequence, 
amitriptyline and lamotrigine should be regarded as drugs of first choice.
Mexiletine and phenytoin have demonstrated efficacy in a small number of 
patients in open studies [46,47]. Carbamazepine, often used in the treatment of 
CP, failed to show effectiveness in a placebo-controlled study, and its use as 
add-on therapy in CP is supported by some experts opinion only [25,37]. The 
novel anticonvulsant gabapentin has shown promising effects in a few patients 
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with CP [48,49]. Its mechanism of action has not yet been fully elucidated, but it 
appears that there is an effect beyond the membrane-stabilizing properties. Its 
good safety profile makes it another candidate drug for controlled studies in CP. 
The IV drugs lidocaine, propofol, and ketamine have shown efficacy in placebo 
controlled trials and seem to have a potential for shortterm control of CP [50-52]. 
Their effects give interesting insights into the etiology of CP and into the bioche-
mical basis of the disorder, but their form of application and their potential side 
effects make them unsuitable for long-term treatment on a routine basis. The 
same is true for intrathecal baclofen [53].
The search for a better treatment of CP should be an urgent priority. From 
the clinical point of view, it should focus on drugs with more favorable safety 
profiles than the membrane-stabilizing agents currently used in combination 
with amitriptyline. It should allow for combination therapy and should an-
swer the question of whether preemptive treatment to reduce the incidence of 
CP can be recommended, analogous to the prevention of postherpetic neural-
gia [54,55].
6.2. non-pharmacological treatment
Invasive motor cortex simulation, deep brain stimulation (DBS), repetitive 
transcranial magnetic stimulation (rTMS), and vestibulocochlear stimulation 
have been tried in patients with CPSP refractory to pharmacotherapy. Corti-
cal simulation for relieving chronic pain was noted during epilepsy surgery by 
Penfield and Jasper who observed relief of burning pain after resection of the 
contralateral postcentral gyrus. Recurrence of pain subsided after resection of 
the contralateral precentral gyrus [56].
Electrical stimulation of the prefrontal cortex resulted in significant alle-
viation of nociceptive response latency in experimental animals [57]. Epidural 
motor cortex stimulation is a less invasive method for central deafferentation 
pain [58].  Motor cortex stimulation activates the intercortical interneurons rat-
her than the corticospinal axons. Stimulation of these neurons affects different 
areas such as thalamocortical projections from ventro-lateral and ventro-an-
terior thalamus, collaterals of corticocortical projections, especially in premo-
tor and post central cortex, and local cortical connections parallel to cortical 
layers. Both orthodromic and antidromic propagation of these stimuli result 
in a cascade of events which modulate neuronal networks of the limbic sy-
stem, thalamus, and brainstem [59-62]. Motor cortex stimulation has also been 
shown to increase noradrenergic activity and increased release of endogenous 
morphine [63,64].
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7. conclusion
Pain problems associated with lesion, disorder or dysfunction of the CNS 
are a common and prominent problem. As suggested by Beric, there is likely a 
number of different CP problems but it is as yet unclear how similar or dissimi-
lar the clinical presentations may be nor whether there are different underlying 
neurobiologic mechanisms [65]. Further studies associating clinical presentation 
with neurobiologic mechanisms are needed. This will hopefully generate more 
effective treatments. Further study is also needed concerning how patients cope 
with pain problems and whether there are any behavioral vulnerability factors.
Finally, whereas impaired pain perception or decreased response to noxious 
stimuli may not be as problematic as CP, this may be of concern and is deserving 
of further study.
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Sažetak
Centralna bol: mehanizmi, semiologija i terapija
Bol koja je posljedica oštećenja ili poremećaja funkcije centralnog živčanog sustava čest 
je problem u svakodnevnoj praksi. Cilj ovog istraživanja bio je prikupiti rezultate dosadašnjih 
studija vezane uz ovu tematiku te prikazati etiologiju, patogenezu, kliničku prezentaciju i mo-
gućnosti liječenja centralne boli. Osobita pažnja posvećena je moždanom udaru kao uzroku 
centralne boli. Općenito, etiologija i patofiziologija centralne boli slabo je istražena, a liječenje 
je dugotrajno i najčeće slabih rezultata. U najvećem broju slučajeva, centralnu bol nije moguće 
u potpunosti izliječiti, može se samo djelomično ublažiti. Od metoda liječenja najčešće se kori-
ste antidepresivi, antiepileptici te stimulacija motoričkog korteksa. Kirurške metode liječenja se 
rijetko koriste jer nisu dugotrajne, njima se centralna bol može samo nakratko ukloniti. Za sada 
ne postoje jasne kliničke smjernice za liječenje centralne boli, postoje samo sporadične studije o 
liječenju iste što je vjerojatno posljedica nedovoljnog poznavanja etiologije i patogeneze central-
ne boli te je u tu svrhu potrebno planirati daljnja istraživanja.  
Ključne riječi: centralna bol; etiologija; liječenje.

